Search research articles
Contact Us
Filters
Showing results (1-10 of 55) with videos related to
Page
of 6
Sort By:
The British Journal of Ophthalmology
|
December 12, 2013
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
Robert L Avery
Ophthalmology
|
October 12, 2010
The plague and macular degeneration
Robert L Avery
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
|
January 13, 2012
Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?
Robert L Avery
Retina (Philadelphia, Pa.)
|
March 2, 2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment
Robert L Avery
Ophthalmology
|
January 24, 2016
Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
Robert L Avery
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
|
August 18, 2009
Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern
Robert L Avery
Current Diabetes Reports
|
October 22, 2016
Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy
Dilsher S Dhoot, Robert L Avery
Expert Opinion on Biological Therapy
|
October 20, 2006
Ranibizumab: treatment in patients with neovascular age-related macular degeneration
Dante J Pieramici, Robert L Avery
JAMA Ophthalmology
|
October 30, 2015
Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis
Robert L Avery, Gabriel M Gordon
Retina (Philadelphia, Pa.)
|
October 11, 2019
Diagnostic and Therapeutic Challenges
Ling Chen, Xinyue Bai, Robert L Avery
Page
of 6
Search research articles
Search
Showing results (1-10 of 55) with videos related to
Sort By:
Page
of 6
The British Journal of Ophthalmology
|
December 12, 2013
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
Robert L Avery
Ophthalmology
|
October 12, 2010
The plague and macular degeneration
Robert L Avery
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
|
January 13, 2012
Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?
Robert L Avery
Retina (Philadelphia, Pa.)
|
March 2, 2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment
Robert L Avery
Ophthalmology
|
January 24, 2016
Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52)
Robert L Avery
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
|
August 18, 2009
Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern
Robert L Avery
Current Diabetes Reports
|
October 22, 2016
Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy
Dilsher S Dhoot, Robert L Avery
Expert Opinion on Biological Therapy
|
October 20, 2006
Ranibizumab: treatment in patients with neovascular age-related macular degeneration
Dante J Pieramici, Robert L Avery
JAMA Ophthalmology
|
October 30, 2015
Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis
Robert L Avery, Gabriel M Gordon
Retina (Philadelphia, Pa.)
|
October 11, 2019
Diagnostic and Therapeutic Challenges
Ling Chen, Xinyue Bai, Robert L Avery
Page
of 6